Medication-taking Preferences & Practices of Patients With Chronic Conditions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01614353|
Recruitment Status : Unknown
Verified December 2012 by Roxanne Vandermause, Washington State University.
Recruitment status was: Recruiting
First Posted : June 7, 2012
Last Update Posted : December 21, 2012
|Condition or disease||Intervention/treatment|
|Any Condition in N73.0 Specified as Chronic Adult Disease Pharmacological Action||Other: Electronic Diaries Other: Hermeneutic Interviews|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Medication-taking Preferences & Practices of Patients With Chronic Conditions|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||November 2013|
All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
Other: Electronic Diaries
Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
Other: Hermeneutic Interviews
Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
- Identify perceptions and behaviors surrounding the medication-taking process of older adults with MCMC. [ Time Frame: Daily electronic diaries for a duration of 30 days ]Data will be obtained in "real time" in that patients will audio record thoughts as they arise in the course of each day using an electronic device, over 30 consecutive days, and will answer questions related to medication use. Findings from end of day prompts will be logged using tables that compare participant demographic characteristics, whether or not the new medication or all prescribed medication was taken, and self-assessed level of wellness.
- Generate an interpretation of the meaning of medication taking among older adults with MCMC. [ Time Frame: 2 Interviews: 1 at enrollment and 1 at 30 days ]In-depth hermeneutic interviews and interpretive phenomenological analyses will be conducted for 15 of the 30 enrolled participants. Patterns and themes that capture common experiences revealed in these data provide language for further investigation and new discussion in areas that have been studied traditionally. Such findings are the characteristic "phenomenological contribution" of qualitative research. Interpretive commentary in the context of social and cultural evidence and extant literature on medication use will be generated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01614353
|Contact: Roxanne K Vandermause, PhDemail@example.com|
|United States, Washington|
|Providence Medical Research Center||Recruiting|
|Spokane, Washington, United States, 99201-4813|
|Sub-Investigator: Katherine Tuttle, MD|
|Sub-Investigator: Gail Burton, RN|
|Sub-Investigator: Duane Sunwold|
|Washington State University||Recruiting|
|Spokane, Washington, United States, 99210-1495|
|Contact: Joshua J Neumiller, PharmD 509-368-6756 firstname.lastname@example.org|
|Principal Investigator: Roxanne Vandermause, PhD|
|Sub-Investigator: Cynthia F Corbett, RN, PhD|
|Principal Investigator: Joshua J Neumiller, PharmD|
|Sub-Investigator: Prabu David, PhD|
|Principal Investigator:||Joshua Neumiller, PharmD||Washington State University|
|Principal Investigator:||Roxanne Vandermause, PhD||Washington State University|